title: Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG.
abstract: Ten patients with Alzheimer's disease were treated with intravenous infusion of physostigmine for 2 h. The acute effects on cognitive function, regional cerebral blood flow, and EEG were compared to placebo (isotonic glucose) using a double-blind cross-over design. Physostigmine causes a limited improvement of psychomotor performance and EEG and an increase of blood flow in the most severely affected cortical areas, predominantly in an early phase of Alzheimer's disease.
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D001921:Brain / Q000098:blood supply*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004569:Electroencephalography; D005071:Evoked Potentials / Q000187:drug effects; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010830:Physostigmine / Q000627:therapeutic use*; D011594:Psychometrics; D012039:Regional Blood Flow / Q000187:drug effects
chemical_list: D010830:Physostigmine